Last updated: March 2026
5-Amino-1MQ is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), studied at the University of Texas Medical Branch. By blocking NNMT — the enzyme that depletes NAD+ in fat cells — it reduces fat cell size and increases cellular NAD+ levels. Discovered between 2019 and 2021, it remains one of the newest metabolic compounds; only mouse data exists.
5-Amino-1MQ is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase). Research conducted at the University of Texas Medical Branch shows it reduces fat cell size and improves metabolic markers in mice.
5-Amino-1MQ blocks NNMT, an enzyme that methylates and depletes NAD+ in fat cells. Blocking NNMT preserves cellular NAD+.
NNMT inhibition in adipocytes leads to reduced fat cell size and decreased lipid accumulation in mouse studies.
By blocking NAD+ consumption by NNMT, cellular NAD+ levels increase, supporting metabolic health.
Unlike most peptides, 5-Amino-1MQ is a small molecule with oral bioavailability in research models.
Preclinical data from mouse studies.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. 5-Amino-1MQ is an extremely new compound with only mouse data. No human clinical trials exist. Not FDA approved. Always consult a healthcare provider.